NAVLIN by EVERSANA

This week from NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, drug approvals and more from across the world. ? Policy: The Trump Campaign’s surprising reversal on the “most favored nations” pharmaceutical pricing model—what does this mean for the 2024 elections? #PolicyUpdate ? Pricing & Reimbursement: Korea’s HIRA Cancer Review Committee’s innovative approach to reviewing new and existing therapy combinations—how will this impact cancer treatment? #HealthcareReform ? HTA: CIRS’s latest workshop report on the upcoming joint clinical assessment (JCA) under EU Regulation—are we ready for the changes starting January 2025? #HealthTechAssessment ? Drug Approval: MHRA’s green light for Ipsen’s Iqirvo (elafibranor) in treating primary biliary cholangitis (PBC)—a new hope for patients. #DrugApproval ? C&G: Six months into the VPAG scheme—ABPI’s review reveals key successes and challenges. What’s next for branded medicines pricing? #PharmaGrowth ? Conferences: Insights from EPP’s Life Science Pricing Forum—Natalie Mochova on the hurdles generic products face with international reference pricing in the digital age. #LifeScienceForum ? Managed Entry Agreements: The potential complications of MHRA’s International Recognition Procedure (IRP) for NICE evaluations—what should stakeholders expect? #ManagedEntry ? Expert Opinion: Dr. Thomas Kaiser reflects on 20 years of IQWiG—celebrating achievements and acknowledging areas for improvement. #ExpertInsight ? Other: GSK Pharma’s bold move into India’s oncology market with two high-value therapies—an exclusive interview with Managing Director Bhushan Akshikar. #PharmaInnovation Read all these stories and much more: https://ow.ly/3wlz50TLZzR

What does operational pricing excellence look like now and in the future? Drawing on an extensive benchmarking survey and detailed data and expertise, Alan Crowther and Maria Merinova will present the state of operational pricing excellence and what the future will hold during this EPP Digital Partner Webinar on 21 November at 3pm CET. REGISTER TODAY: https://ow.ly/slPl50TL4SV

Register to attend today: https://ow.ly/iFTB50Tlj5E Join Chad Gibson, EVERSANA's Senior Vice President for NAVLIN Consulting, in the upcoming EPP Partner Webinar, "Price & Market Access in the Pipeline: How? P&MA is Evolving to Meet New Pipeline Challenges." During this informative session, we'll tackle innovative ways to do early asset valuation and how to think about indication sequencing due to changing global rules like the United States Inflation Reduction Act.

Join Us at EPP 2024: https://ow.ly/87EL50TgIFL Alan Crowther, General Manager, Global Pricing & Access Solutions, will present on October 11 to conference attendees on, “The State of Operational Pricing: Benchmarking & Best Practices”. Join Alan for this comprehensive review of survey and additional data on the data, processes, people tools and data that companies are using to drive their operational pricing teams.? Don’t miss this informative session on October 10 – register for the conference today.

Read the NAVLIN Last Week in Review Now: https://ow.ly/u8ws50TFBLS This week from NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, drug approvals and more from across the world. ? Policy: Discover how the new Medical Research Act (MFG) in Germany is shaking up the landscape with confidential pricing and clinical trial incentives. ? Regulation: The FDA’s latest move on Eli Lilly’s tirzepatide products—what it means for compounding pharmacies and patent protection. ? Pricing & Reimbursement: Unpack the finalized guidance from CMS on the second cycle of Medicare Drug Price Negotiations under the IRA. ? HTA: NHS England’s phased rollout of Mounjaro (tirzepatide) for obesity management—who qualifies now and what’s next? ? C&G Therapy: WuXi AppTec and WuXi Biologics consider selling pharmaceutical units amidst new U.S. legislation—what’s at stake? ? Industry Deals & Agreements: Gilead’s strategic partnerships for lenacapavir licensing—will it truly meet global health needs? ? Managed Entry Agreements: OECD’s latest findings on the surge of approved cancer medicines in the EU and OECD countries—what does this mean for access? And so much more... Click through to read more on each story and stay informed! #MarketAccess #PricingStrategy #PharmaNews #HealthcarePolicy #RegulatoryUpdates #HTA #CGTherapy #IndustryDeals #ManagedEntryAgreements

Schedule a meeting at EPP 2024: https://ow.ly/pfHW50T6yY1 Experience the unique opportunity to discover best practices and leading-edge solutions to your pricing, marketing access and reimbursement challenges. Visit EVERSANA’s team of experts behind NAVLIN by EVERSANA in booth #3 or schedule a meeting today.

Register to attend today: https://ow.ly/iFTB50Tlj5E Join Chad Gibson, EVERSANA's Senior Vice President for NAVLIN Consulting, in the upcoming EPP Partner Webinar, "Price & Market Access in the Pipeline: How? P&MA is Evolving to Meet New Pipeline Challenges." During this informative session, we'll tackle innovative ways to do early asset valuation and how to think about indication sequencing due to changing global rules like the United States Inflation Reduction Act.

What you need to know: https://ow.ly/zGIo50Tujgo Are you prepared for the EU Health Technology Assessment (HTA) Regulations that will take effect in January, 2025? While new regulations promise a more streamlined, harmonized assessment process, there are implications to consider. Shivani Shah, Consultant to NAVLIN Market Access & HTA Consulting, breaks down the top things you need to know in order to be prepared.

Read the NAVLIN Last Week in Review Now: https://ow.ly/I3pZ50Tufxi This week from NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, drug approvals and more from across the world. Policy: The Czech Republic’s Ministry of Health is set to discuss an amendment to the Public Health Insurance Act, potentially revising the rules for maximum pricing of medicinal products. #PolicyUpdate #PharmaPricing Pricing & Reimbursement: The HRSA has warned J&J about potential penalties if it continues its rebate system for Stelara and Xarelto under the 340B Drug Pricing Program. #DrugPricing #Reimbursement HTA: NICE has recommended Daiichi Sankyo’s Vanflyta for various treatment stages of newly diagnosed FLT3-ITD-positive AML in its final draft guidance. #HTA #Oncology Drug Approval: China’s NMPA announced the approval of 31 innovative drugs between January and August 2024. #DrugApproval #Innovation C&G Therapy: Belgium and the Netherlands will pursue separate reimbursement negotiations for CSL Behring’s Hemgenix after a joint assessment via the BeNeLuxA initiative. #GeneTherapy #Reimbursement Managed Entry Agreements: A survey across OECD and EU member countries reveals mixed feelings about sharing net pricing data for medicines. #ManagedEntry #PharmaEconomics Conferences: NAVLIN Daily is proud to be an official media partner for MDRP Summit 2024, happening September 23-25 in Chicago. #MDRP2024 #PharmaConference Other: The NMPA’s CDE has published its pilot work plan for the Patient-Centered Rare Disease Drug Development initiative (CARE Plan). #RareDiseases #DrugDevelopment And so much more... Click through to read more on each story and stay informed! ???

Join Us at EPP 2024: https://ow.ly/87EL50TgIFL Alan Crowther, General Manager, Global Pricing & Access Solutions, will present on October 11 to conference attendees on, “The State of Operational Pricing: Benchmarking & Best Practices”. Join Alan for this comprehensive review of survey and additional data on the data, processes, people tools and data that companies are using to drive their operational pricing teams.? Don’t miss this informative session on October 10 – register for the conference today.